- Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia2022 | Third Faculty of Medicine
- Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study2020 | First Faculty of Medicine
- Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy2022 | Third Faculty of Medicine
- Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy2022 | Central Library of Charles University
- Frontline treatment with the combination obinutuzumab +/- chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group2020 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Pharmaco-refractory chronic heart failure - the need for drug level tailored management2012 | Faculty of Medicine in Hradec Králové
- Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study2023 | Faculty of Medicine in Pilsen
- Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study2018 | Publication without faculty affiliation
